



Science reporters always have a lot to
think about between the time they
receive press materials from a journal
and the time they have to decide
whether to play up an advance or
ignore it altogether. Journals,
universities and companies do their
best to be good salespeople — to
market their product for mass
consumption. Science reporters, too,
are looking for juicy stories. But they
don’t want to embarrass themselves
by being taken in by hype.
A case study of this was a story
published in the April 1 issue of the
journal Nature Genetics. The journal’s
own promotional material
highlighted the development of an
“artificial human chromosome.”
Soon, reporters received news
releases from Case Western Reserve
University and a Cleveland biotech
company called Athersys Inc.
In the wake of Dolly the lamb, an
artificial human chromosome sounds
pretty sexy. Surely the headline
alone would lead a reader to
contemplate entire artificial human
beings. The ‘hook’ for the story was
certainly there. But how much would
remain once the rest of the story was
reeled in? Different reporters
reached different conclusions.
The stories that played up the
therapeutic potential of the research
generally got the most prominent
display. “Scientists in Ohio have
created the first artificial
chromosomes, an achievement that
my someday allow doctors to alter
people’s genetic inheritance or cure
genetic diseases by slipping genetic
‘cassettes’ directly into cells,” wrote
Rick Weiss of the Washington Post.
That angle earned his article a place
on the front page.
The Los Angeles Times also put the
study on page one, calling it “a major
milestone in the study of human
heredity.” The Columbus Dispatch said
the research “may not be as
sensational as Dolly, the cloned
sheep, but it likely is more significant
in terms of human health.” That
story, too, was on the front page.
But the story ended up inside the
San Jose Mercury News, where the
reporter took more of a business
angle. Newsday on Long Island, the
nation’s sixth-largest newspaper, put
the story on page 28. The New York
Times took a particularly soft approach,
waiting until the second paragraph of
its story to announce the news (and
cautiously at that). That article ended
up on page three of Science Times, the
paper’s weekly science section. And
prominent science reporters in San
Francisco and Boston didn’t bother
with the story at all.
In the wake of Dolly the lamb, an
artificial human chromosome
sounds pretty sexy
Reporters and editors review dozens
of potential stories in a week. Stories
that are heavily promoted get a bit
more attention — if nothing else,
everyone knows that other people in
the news organization read the
competition, and nobody likes to be
asked, “why didn’t we have that
story?” even if the story doesn’t live
up to its billing.
And sometimes reporters are
rewarded for digging into a story
that may seem to be over hyped.
Rick Weiss at the Washington Post
explored the ethical issues.
“Artificial chromosomes will not
directly facilitate the cloning of
animals or people, medical ethicists
and others said, but they represent
a similarly surprising and somewhat
disconcerting new power over basic
biological and reproductive
processes.”
The Washington Post used a great
deal of ink discussing how artificial
chromosomes could help in gene
transfer experiments. But it wasn’t
until the very last paragraph that the
story quoted a skeptic noting that
other approaches to gene therapy are
much more advanced and likely to
achieve the same ends sooner.
In contrast, the New York Times
story dwelt on the many failures of
gene therapy and the practical
limitations of using artificial
chromosomes for gene therapy. The
writer even put W. French Anderson’s
words of caution about the discovery
higher in the story than the details of
the announcement itself. (But the
New York Times did not mention, as
the Los Angeles Times did, that
Anderson is working with a competing
company on gene therapy strategies.)
Just as scientists prefer to publish
in the best journals, journalists prefer
to have their stories on the front
page. As the story of the artificial
chromosome attests, reporters can
control to some extent where their
stories will appear in the paper, by
their decisions about how much to
cheer a new advance, or how
prominently to display the caveats.
But this episode also shows that
prominent reporters aren’t shy about
downplaying a story or ignoring it
altogether, even though it’s fairly
obvious that a punchy lead paragraph
and a few excited quotes near the
top of the story give it a good chance
of landing on the front page,
particularly on a slow news day, as
was the case in this instance.
The truth is that reporters, like
everybody else, generally do a poor
job of predicting which development
will be a major advance and which
will fizzle. We have learned to be
cautious over the years about
promising too much about therapies
that are at the clinical stage — and
which people may rush to out of
desperation. But if it’s a more basic
advance, it’s easier to promise a little
more. If it fades, it will be forgotten.
If it blossoms, we’ll congratulate
ourselves for being prescient.
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